Press release
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Fabulous Opportunities, Complete Analysis of Current Industry Trends 2024-2031 - Illumina Inc., Guardant Health Inc., APIS Assay Technologies Ltd.
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market
Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: - https://datamintelligence.com/download-sample/esr1-mutated-metastatic-breast-cancer-diagnostics-market
What is the projected growth rate (CAGR) of the Global ESR1 Mutated Metastatic Breast Cancer Diagnostics market from 2024 to 2031, and what is the market value expected to change by 2031?
The ESR1 Mutated Metastatic Breast Cancer Diagnostics Market is valued at a significant CAGR during the forecast period (2024-2031).
ESR1 mutated metastatic breast cancer diagnostics involve testing for mutations in the ESR1 gene, which is associated with resistance to certain hormone therapies in breast cancer. Detection of ESR1 mutations can help guide treatment decisions, as these mutations may lead to reduced effectiveness of estrogen receptor-targeted therapies. Diagnostic methods typically include genetic testing, sequencing, and biopsy analysis. Identifying ESR1 mutations allows for personalized treatment options, such as switching to alternative therapies or combination therapies that are more likely to be effective. Accurate diagnosis improves outcomes by tailoring treatments to the specific mutation profile.
Key Developments:
❁ In September 2023, Lunit entered into a distribution agreement with Guardant Health, a U.S.-based precision oncology company, to bring Guardant Health's cancer diagnostic products to the Korean market. This partnership aims to expand access to advanced cancer diagnostics in Korea, leveraging Guardant Health's expertise in precision oncology and Lunit's established presence in the healthcare sector. Through this collaboration, both companies strive to enhance cancer care in Korea by offering cutting-edge diagnostic tools that support earlier and more accurate cancer detection, ultimately helping to improve patient outcomes.
List of the Key Players in the ESR1 Mutated Metastatic Breast Cancer Diagnostics Market:
Illumina Inc., Guardant Health Inc., APIS Assay Technologies Ltd., Gencurix Inc., RainSure Scientific, NeoGenomics Inc., Sysmex Corporation, Asuragen Inc., CUSABIO TECHNOLOGY LLC and Cayman Chemical Company.
Research Process:
Both primary and secondary data sources have been used in the global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
Segment Covered in the ESR1 Mutated Metastatic Breast Cancer Diagnostics Market:
By Test Type: NGS Based, PCR Based.
By Sample Type: Tissue, Plasma.
By End User: Oncology Centers, Diagnostic Centers, Cancer Research Institutes.
Regional Breakout:
The global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.
✫ North America (U.S., Canada, Mexico)
✫ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
✫ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
✫ South America (Colombia, Brazil, Argentina, Rest of South America)
✫ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Get Year End Discounts on Premium Report:- https://www.datamintelligence.com/buy-now-page?report=esr1-mutated-metastatic-breast-cancer-diagnostics-market
This Report Unveils:
✔ Go to Market Strategy- A roadmap to successfully product launch or service in the target market.
✔ Gain a clear picture of the market's health and growth trajectory through neutral analysis.
✔ Deep Market Insights delve into development trends, competitor landscape, supply and demand dynamics, brand share & pricing analysis year-over-year growth patterns, and key players' performance.
✔ Upon request, we can provide customized reports focusing on specific regions or countries, offering a granular view of their markets.
✔ Identify high-potential niche segments and regions poised for significant expansion.
✔ Analysis of Market Size (historical and forecast) Total Addressable Market (TAM), Serviceable Available Market (SAM), and Serviceable Obtainable Market (SOM) to understand the market's overall size and your achievable market share.
✔ Gain a comprehensive understanding of the competitive landscape, including market share distribution, key players (innovators, startups, laggards, and pioneers), and their respective strengths and weaknesses.
**The full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted**
Chapter Outline:
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: key insights, key emerging trends, etc.
Chapter 3: Manufacturers competitive analysis, detailed analysis of ESR1 Mutated Metastatic Breast Cancer Diagnostics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 5 & 6: Revenue of ESR1 Mutated Metastatic Breast Cancer Diagnostics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the ESR1 Mutated Metastatic Breast Cancer Diagnostics market in different market segments.
Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the ESR1 Mutated Metastatic Breast Cancer Diagnostics market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: The main points and conclusions of the report.
Get Customization in the report as per your requirements:- https://datamintelligence.com/customize/esr1-mutated-metastatic-breast-cancer-diagnostics-market
Frequently Asked Questions
☞ What is the expected growth rate of the global ESR1 Mutated Metastatic Breast Cancer Diagnostics market for the forecast period?
☞ What are the key driving factors that are responsible to shape the fate of the ESR1 Mutated Metastatic Breast Cancer Diagnostics market during the forecast period?
☞ What will be the overall size of the market during the analysis period?
☞ What are the prominent market trends which influence the development of the ESR1 Mutated Metastatic Breast Cancer Diagnostics market across various regions?
☞ Who are the key market players and the market strategies that have helped them to secure the leading position in the global market?
☞ What are the challenges and threats that are likely to act as a barrier to the growth of the ESR1 Mutated Metastatic Breast Cancer Diagnostics market?
☞ What are the major opportunities that the companies can get to attain success in the world?
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Fabulous Opportunities, Complete Analysis of Current Industry Trends 2024-2031 - Illumina Inc., Guardant Health Inc., APIS Assay Technologies Ltd. here
News-ID: 3733271 • Views: …
More Releases from DataM Intelligence 4market Research LLP
Smart Classroom Market Set to Grow at 17.4% CAGR Driven by Digital Learning | To …
Global Smart Classroom Market is expected to reach at a CAGR of 17.4% within the forecast period (2024-2031).
According to DataM Intelligence has published a new research report on "Smart Classroom Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of…
Revenue Cycle Management Market to Reach US$ 291.19 Billion by 2033 at 12.4% CAG …
The global revenue cycle management market size reached US$ 102.16 billion in 2024 is expected to reach US$ 291.19 billion by 2033, growing at a CAGR of 12.4% during the forecast period 2025-2033.
According to DataM Intelligence has published a new research report on "Revenue Cycle Management Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top…
IT Asset Management Software Market to Reach US$ 4.14 Billion by 2033 at 7.11% C …
The global IT asset management software market reached US$ 2,132.33 million in 2023, with a rise to US$ 2,255.49 million in 2024, and is expected to reach US$ 4,139.20 million by 2033, growing at a CAGR of 7.11% during the forecast period 2025-2033.
According to DataM Intelligence has published a new research report on "IT Asset Management Software Market Size 2025". The report explores comprehensive and insightful Information about various…
Debt Collection Software Market Trends: Predictive Analytics, Cloud, and Omnicha …
Debt Collection Software Market is growing at a CAGR of 9.9 % in the forecast period (2024-2031)
According to DataM Intelligence has published a new research report on "Debt Collection Software Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of…
More Releases for ESR1
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Set for Steady Growth A …
The global market for ESR1 mutated metastatic breast cancer diagnostics is projected to grow from USD 64.61 million in 2025 to USD 92.92 million by 2035, reflecting a compound annual growth rate (CAGR) of 3.7%, according to the latest market analysis. This growth trajectory is driven by the rising prevalence of ESR1 mutations in metastatic breast cancer patients, increasing demand for early and precise diagnostic solutions, and ongoing innovations in…
ESR1 mutated metastatic breast cancer Market Analysis 2034 - Competitive Landsca …
The ESR1-mutated metastatic breast cancer companies are AstraZeneca, Olema Pharmaceuticals, Arvinas, Sermonix Pharmaceuticals, Roche, Eli Lilly and Company, H3 Biomedicine, Eisai, Pfizer, Sun Pharma Advanced Research Company, Zenopharm, Daiichi Sankyo, and others.
ESR1-mutated metastatic breast cancer market, valued at approximately USD 1.3 billion in 2023, is projected to experience substantial growth during the forecast period (2024-2034). Furthermore, the US accounts for the largest market share, representing approximately 63% of the total…
United States ESR1 Mutated Metastatic Breast Cancer Diagnostics Market valuation …
"The global ESR1 mutated metastatic breast cancer diagnostics market size reached US$ 63.51 Million in 2024 from US$ 61.05 Million in 2023 and is expected to reach US$ 93.21 Million by 2033, growing at a CAGR of 4.4% during the forecast period 2025-2033." As per DataM intelligence research report
Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/esr1-mutated-metastatic-breast-cancer-diagnostics-market?sp
United States: Recent Industry Developments
✅ In September 2025, Guardant Health launched…
FDA Approves INLURIYO (Imlunestrant): A Game-Changer for ESR1-Mutated Metastatic …
The pharmaceutical landscape for metastatic breast cancer treatment has witnessed a significant milestone with the FDA approval of INLURIYO (imlunestrant) on September 25, 2025. Eli Lilly's innovative, world-first oral selective estrogen receptor degrader (SERD) represents the first endocrine therapy innovation specifically targeting ESR1 mutations in over two decades, addressing a critical unmet medical need in estrogen receptor-positive (ER+), HER2-negative breast cancer patients.
Image: https://www.abnewswire.com/upload/2025/09/ccb2e17e2f3a2721c027dabdf0f1bd92.jpg
The pharmaceutical landscape for metastatic breast cancer treatment…
ESR1-Mutated Metastatic Breast Cancer Market Set for Significant Growth by 2034, …
DelveInsight's "ESR1 Mutated Metastatic Breast Cancer - Market Insight, Epidemiology And Market Forecast - 2034" [https://www.delveinsight.com/report-store/esr1-mutated-metastatic-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr] report delivers comprehensive insights into the disease landscape, historical and forecasted epidemiology, as well as ESR1 Mutated Metastatic Breast Cancer market trends across the 7MM (United States, EU4 [Germany, France, Italy, and Spain], United Kingdom, and Japan). The report reveals that the ESR1-mutated metastatic breast cancer market, valued at approximately USD 1.3 billion in…
ESR1-Mutated Metastatic Breast Cancer Market Industry Analysis by Size, Share, G …
Introduction
The ESR1-Mutated Metastatic Breast Cancer Market focuses on a specific subtype of hormone receptor-positive (HR+), HER2-negative metastatic breast cancer characterized by mutations in the estrogen receptor 1 (ESR1) gene. These mutations confer resistance to standard endocrine therapies such as aromatase inhibitors, making the disease more difficult to manage and highlighting the need for novel targeted approaches.
In recent years, the emergence of oral selective estrogen receptor degraders (SERDs), next-generation endocrine therapies,…
